Search - tctmd.com

Displaying 201 - 220 of 310

Sort: Relevancy | Date

News Daily News

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

L.A. McKeown

July 01, 2015

News Daily News

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Yael L. Maxwell

June 26, 2015

News Daily News

ISAR-DESIRE 3: Un Balón Recubierto de Fármaco Confiere un Efecto Reestenótico Duradero en la Reestenosis del SLF

L.A. McKeown

June 03, 2015

News Daily News

ISAR-DESIRE 3: Drug-Coated Balloon Shows Durable Antirestenotic Effect in DES Restenosis

L.A. McKeown

June 03, 2015

News Conference News EuroPCR 2015

Studies Provide Encouraging Results for DCB in Long SFA Lesions

Caitlin E. Cox

May 22, 2015

News Daily News

DCB Matches DES in Treating ‘Real-World’ Patients With In-Stent Restenosis

March 04, 2015

News Daily News

PCI No Less Effective in High-BMI Patients Despite Greater Plaque Burden

January 28, 2015

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

News Daily News

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

Caitlin E. Cox

October 24, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

News Daily News

Drug-Eluting Balloon Fails for Below-the-Knee Lesions in Critical Limb Ischemia Patients

Todd Neale

October 10, 2014

Presentation TCT 2014

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff

September 16, 2014

Presentation TCT 2014

Do Drug-Eluting Balloons Have Anything to Offer for Bifurcation Treatment? From Theory to Data

Presenter: Bernard R. Chevalier, Leif Thuesen, Ricardo A. Costa, Kenneth Chin

September 15, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

News Industry News

New Study Finds Everolimus-Eluting Stents Provide Superior Clinical Outcomes Compared to Drug-Eluting Balloons in Patients with Drug-Eluting Stent Restenosis

September 14, 2014

News Conference News TCT 2014

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

September 13, 2014

News Industry News

Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance

September 11, 2014

News Industry News

Boston Scientific Receives CE Mark For Ranger™ Drug-Coated Balloon

July 14, 2014

News Daily News

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

L.A. McKeown

June 17, 2014

Advertisement

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

ISAR-DESIRE 3: Un Balón Recubierto de Fármaco Confiere un Efecto Reestenótico Duradero en la Reestenosis del SLF

ISAR-DESIRE 3: Drug-Coated Balloon Shows Durable Antirestenotic Effect in DES Restenosis

Studies Provide Encouraging Results for DCB in Long SFA Lesions

DCB Matches DES in Treating ‘Real-World’ Patients With In-Stent Restenosis

PCI No Less Effective in High-BMI Patients Despite Greater Plaque Burden

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Drug-Eluting Balloon Fails for Below-the-Knee Lesions in Critical Limb Ischemia Patients

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Do Drug-Eluting Balloons Have Anything to Offer for Bifurcation Treatment? From Theory to Data

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

New Study Finds Everolimus-Eluting Stents Provide Superior Clinical Outcomes Compared to Drug-Eluting Balloons in Patients with Drug-Eluting Stent Restenosis

PEPCAD-DES at 3 Years: Paclitaxel-Coated Balloon Holds Advantage for DES Restenosis

Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance

Boston Scientific Receives CE Mark For Ranger™ Drug-Coated Balloon

Un Panel Asesor de la FDA Aprueba un Balón recubierto de Paclitaxel para el Manejo de la Enfermedad Femoropoplítea

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content